An open, prospective trial investigating pharmacokinetics and safety (Part A) of the human normal immunoglobulin for intravenous infusion (IVIG) BT090 and tolerability and safety of escalating infusion rates (Part B) in patients with primary immunodeficiency disease (PID)

Biotest AG0 个研究点目标入组 30 人开始时间: 2010年8月6日最近更新: 2012年5月8日

适应症

试验速览

暂无简介。

•- Male or female patients (age 6–65 years)
•- Diagnosis of common variable immunodeficiency (CVID) or X-linked agammaglobulinemia (XLA) as defined by ESID/PAGID diagnostic criteria
•- Written informed consent
•- Established replacement therapy with any IVIG reference preparation during the previous 6 months, including documentation of IgG trough levels,
•-Established replacement therapy with a single IVIG reference preparation for at least 3 months prior to treatment start with BT090, with constant IVIG dose that had not changed by ± 50% of the mean dose as well as dosage interval for at least 3 months prior to study entry and had maintained IgG trough levels of =6g/L
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 10
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 20
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•- Pregnancy or unreliable contraceptive measures or lactation period (women only)
•- Known intolerance to immunoglobulins or comparable substances (e.g. vaccination reaction)
•- Known intolerance to proteins of human origin
•- Participation in another clinical trial within 90 days before entering the trial or during the trial and/or previous participation in this trial
•- Inability or lacking motivation to participate in the trial
•- Selective, absolute IgA deficiency or known antibodies to IgA
•- Positive diagnostics of hepatitis B and hepatitis C
•- Positive HIV test
•- Acquired medical condition known to cause secondary immune deficiency such as CLL, lymphoma, multiple myeloma
•- Patients with protein losing enteropathies, hypoalbuminaemia

发起方